check web redirect url status code checker

Check server response of

Server response
NS records
Whois domain
Response headers
Request headers
Raw HTML code
301 Moved Permanently - cvbt.com
HTTP Status: 301
User-Agent: Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; [email protected])
Date: Fri, 16 May 2025 16:19:13 GMT
Content-Type: text/html
Content-Length: 166
Connection: keep-alive
Location: https://www.venturistherapeutics.com/
X-Cluster-Name: us-east-1-prod-hosting-red

HTTP Code 301 Moved Permanently

301 status code means that the requested resource has been permanently moved to a new URL. All future requests should use the new address.

When is Code 301 used?

  • When changing a website domain
  • When modifying URL structures
  • When setting up redirects for SEO

What does Code 301 mean for the user?

The browser will automatically redirect the user to the new address, and search engines will update their indexes.

200 OK - http://venturistherapeutics.com
HTTP Status: 200
User-Agent: Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; [email protected])
Date: Fri, 16 May 2025 16:19:13 GMT
Content-Type: text/html
Transfer-Encoding: chunked
Connection: keep-alive
CF-Ray: 940c320878c982a1-ARN
CF-Cache-Status: HIT
Age: 231091
Last-Modified: Thu, 17 Apr 2025 17:46:16 GMT
Strict-Transport-Security: max-age=31536000
surrogate-control: max-age=2147483647
surrogate-key: www.venturistherapeutics.com 5d929ea754fd0f4955087956 pageId:613c16a17b270d28cedf1bf5
x-lambda-id: 000b34b7-2ffd-4b12-8be7-77808b7a69e2
vary: Accept-Encoding
Set-Cookie: _cfuvid=3_u8PvR507nWVsPovRh0ktfnPFtdGVAc9jIwN6.sfDM-1747412353430-0.0.1.1-604800000; path=/; domain=.www.venturistherapeutics.com; HttpOnly; Secure; SameSite=None
Server: cloudflare
alt-svc: h3=":443"; ma=86400

HTTP Code 200 OK

200 status code is a standard successful HTTP server response. It means that the client’s request (e.g., from a browser) was successfully processed, and the server is delivering the requested data.

When is Code 200 used?

  • When loading a web page
  • When successfully receiving an API response
  • When processing a form or another HTTP request

What does Code 200 mean for the user?

The user receives content without errors, and the page or application functions properly. If Code 200 is accompanied by data, the browser or program processes and displays it to the user.

GET / HTTP/1.1
Host: cvbt.com
Accept: */*
User-Agent: Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; [email protected])

<!DOCTYPE html><!-- This site was created in Webflow. https://webflow.com --><!-- Last Published: Wed Jan 08 2025 19:43:54 GMT+0000 (Coordinated Universal Time) --><html data-wf-domain="www.venturistherapeutics.com" data-wf-page="613c16a17b270d28cedf1bf5" data-wf-site="5d929ea754fd0f4955087956" data-wf-status="1"><head><meta charset="utf-8"/><title>Venturis Therapeutics</title><meta content="width=device-width, initial-scale=1" name="viewport"/><meta content="Webflow" name="generator"/><link href="https://cdn.prod.website-files.com/5d929ea754fd0f4955087956/css/venturis.webflow.1ab2cf6b4.css" rel="stylesheet" type="text/css"/><link href="https://fonts.googleapis.com" rel="preconnect"/><link href="https://fonts.gstatic.com" rel="preconnect" crossorigin="anonymous"/><script src="https://ajax.googleapis.com/ajax/libs/webfont/1.6.26/webfont.js" type="text/javascript"></script><script type="text/javascript">WebFont.load({  google: {    families: ["Lato:100,100italic,300,300italic,400,400italic,700,700italic,900,900italic","Exo:100,100italic,200,200italic,300,300italic,400,400italic,500,500italic,600,600italic,700,700italic,800,800italic,900,900italic","Exo 2:100,200,300,regular"]  }});</script><script src="https://use.typekit.net/qqe4kpj.js" type="text/javascript"></script><script type="text/javascript">try{Typekit.load();}catch(e){}</script><script type="text/javascript">!function(o,c){var n=c.documentElement,t=" w-mod-";n.className+=t+"js",("ontouchstart"in o||o.DocumentTouch&&c instanceof DocumentTouch)&&(n.className+=t+"touch")}(window,document);</script><link href="https://cdn.prod.website-files.com/5d929ea754fd0f4955087956/5d929ea754fd0f979408798b_cvbt-favicon-alt.jpg" rel="shortcut icon" type="image/x-icon"/><link href="https://cdn.prod.website-files.com/5d929ea754fd0f4955087956/5d929ea754fd0f69d108798e_cvbt-webclip-alt.jpg" rel="apple-touch-icon"/><script async="" src="https://www.googletagmanager.com/gtag/js?id=UA-156069850-1"></script><script type="text/javascript">window.dataLayer = window.dataLayer || [];function gtag(){dataLayer.push(arguments);}gtag('js', new Date());gtag('config', 'UA-156069850-1', {'anonymize_ip': true});</script></head><body class="body"><div data-collapse="medium" data-animation="default" data-duration="400" data-w-id="345372dd-3966-8d53-34db-1b6dbde96c1a" data-easing="ease" data-easing2="ease" role="banner" class="navbar banner w-nav"><div class="w-container"><a href="/" aria-current="page" class="home-button w-nav-brand w--current"><img src="https://cdn.prod.website-files.com/5d929ea754fd0f4955087956/62c49ef8fb86dc58d097bf5b_Venturis-therapeutics-logo.png" width="115" data-w-id="345372dd-3966-8d53-34db-1b6dbde96c1d" sizes="(max-width: 767px) 97.734375px, (max-width: 991px) 13vw, 115px" alt="" srcset="https://cdn.prod.website-files.com/5d929ea754fd0f4955087956/62c49ef8fb86dc58d097bf5b_Venturis-therapeutics-logo-p-500.png 500w, https://cdn.prod.website-files.com/5d929ea754fd0f4955087956/62c49ef8fb86dc58d097bf5b_Venturis-therapeutics-logo-p-800.png 800w, https://cdn.prod.website-files.com/5d929ea754fd0f4955087956/62c49ef8fb86dc58d097bf5b_Venturis-therapeutics-logo-p-1080.png 1080w, https://cdn.prod.website-files.com/5d929ea754fd0f4955087956/62c49ef8fb86dc58d097bf5b_Venturis-therapeutics-logo-p-1600.png 1600w, https://cdn.prod.website-files.com/5d929ea754fd0f4955087956/62c49ef8fb86dc58d097bf5b_Venturis-therapeutics-logo.png 1641w" class="home"/></a><div class="menu-button w-nav-button"><div class="icon w-icon-nav-menu"></div></div><nav role="navigation" id="w-node-_345372dd-3966-8d53-34db-1b6dbde96c20-bde96c1a" class="nav-menu w-nav-menu"><a href="/" aria-current="page" class="navbar-text w-nav-link w--current">Home</a><a href="/leadership" class="navbar-text w-nav-link">Leadership</a><a href="/pipeline" class="navbar-text w-nav-link">Pipeline</a><a href="/investors" class="navbar-text w-nav-link">Investors</a><a href="/news" class="navbar-text w-nav-link">News</a><a href="/contact-us" class="navbar-text w-nav-link">Contact</a></nav></div></div><div class="background-top-section"><div class="div-block-22"><div data-w-id="378a2e34-a661-95e8-d84c-cac7399f633f" style="opacity:0;-webkit-transform:translate3d(0, 40PX, 0) scale3d(1, 1, 1) rotateX(0) rotateY(0) rotateZ(0) skew(0, 0);-moz-transform:translate3d(0, 40PX, 0) scale3d(1, 1, 1) rotateX(0) rotateY(0) rotateZ(0) skew(0, 0);-ms-transform:translate3d(0, 40PX, 0) scale3d(1, 1, 1) rotateX(0) rotateY(0) rotateZ(0) skew(0, 0);transform:translate3d(0, 40PX, 0) scale3d(1, 1, 1) rotateX(0) rotateY(0) rotateZ(0) skew(0, 0)" class="container-2 w-container"><div id="w-node-cc79d01a-5460-b46a-c047-30fe17ca5671-cedf1bf5" data-w-id="cc79d01a-5460-b46a-c047-30fe17ca5671" style="opacity:0;-webkit-transform:translate3d(0PX, 11PX, 0PX) scale3d(1, 1, 1) rotateX(0) rotateY(0) rotateZ(0) skew(0, 0);-moz-transform:translate3d(0PX, 11PX, 0PX) scale3d(1, 1, 1) rotateX(0) rotateY(0) rotateZ(0) skew(0, 0);-ms-transform:translate3d(0PX, 11PX, 0PX) scale3d(1, 1, 1) rotateX(0) rotateY(0) rotateZ(0) skew(0, 0);transform:translate3d(0PX, 11PX, 0PX) scale3d(1, 1, 1) rotateX(0) rotateY(0) rotateZ(0) skew(0, 0);transform-style:preserve-3d" class="body-header-2-copy">VENTURIS THERAPEUTICS OVERVIEW</div><div id="w-node-_35baacc8-3948-084d-97b9-546c47de55eb-cedf1bf5" data-w-id="35baacc8-3948-084d-97b9-546c47de55eb" style="opacity:0;-webkit-transform:translate3d(0, 11PX, 0) scale3d(1, 1, 1) rotateX(0) rotateY(0) rotateZ(0) skew(0, 0);-moz-transform:translate3d(0, 11PX, 0) scale3d(1, 1, 1) rotateX(0) rotateY(0) rotateZ(0) skew(0, 0);-ms-transform:translate3d(0, 11PX, 0) scale3d(1, 1, 1) rotateX(0) rotateY(0) rotateZ(0) skew(0, 0);transform:translate3d(0, 11PX, 0) scale3d(1, 1, 1) rotateX(0) rotateY(0) rotateZ(0) skew(0, 0)" class="body-header-3">Our Approach in Science and Technology:</div><div id="w-node-cc79d01a-5460-b46a-c047-30fe17ca5673-cedf1bf5" data-w-id="cc79d01a-5460-b46a-c047-30fe17ca5673" style="opacity:0" class="body-copy home">Venturis Therapeutics, Inc. is a clinical stage biopharmaceutical company advancing novel therapeutics to address diseases such as diabetic wounds, severe ischemic heart disease and peripheral artery disease. Our pre-clinical therapeutic programs include erectile dysfunction, infarct stroke, degenerative disk disease and Parkinson’s Disease. Venturis Therapeutics, Inc. is focused on targeted delivery of next generation molecules which will improve the quality of life for those suffering from vascular dysfunction.</div><div id="w-node-cc79d01a-5460-b46a-c047-30fe17ca56be-cedf1bf5" data-w-id="cc79d01a-5460-b46a-c047-30fe17ca56be" style="opacity:0;-webkit-transform:translate3d(0, 11PX, 0) scale3d(1, 1, 1) rotateX(0) rotateY(0) rotateZ(0) skew(0, 0);-moz-transform:translate3d(0, 11PX, 0) scale3d(1, 1, 1) rotateX(0) rotateY(0) rotateZ(0) skew(0, 0);-ms-transform:translate3d(0, 11PX, 0) scale3d(1, 1, 1) rotateX(0) rotateY(0) rotateZ(0) skew(0, 0);transform:translate3d(0, 11PX, 0) scale3d(1, 1, 1) rotateX(0) rotateY(0) rotateZ(0) skew(0, 0)" class="body-header-2 news">In The News</div><div id="w-node-_50a58460-e9c4-00f7-a1b1-53512e897300-cedf1bf5" data-w-id="50a58460-e9c4-00f7-a1b1-53512e897300" style="opacity:0" class="body-copy b4news">We employ human proteins from the Fibroblast Growth Factor family. Our lead candidate stimulates the growth of new blood vessels when administered to ischemic organs and tissues. These anatomical targets are shown in our pipeline section.</div><div id="w-node-e5da6aef-79c0-8369-095a-a57aed7b9ca8-cedf1bf5" class="hp-news-div"><a data-w-id="17249fd3-129b-5688-3c26-10f2edecb8aa" style="opacity:0" href="https://cdn.prod.website-files.com/5d929ea754fd0f4955087956/648231a8145ec6158eeaf3e9_PR%20Armstrong%20VT%20final.pdf" target="_blank" class="hp-news-trigger-2 w-inline-block"><div class="hp-megaphone-2"></div><div class="div-block-10"><div class="hp-news-title-2"><strong class="bold-text-3">Venturis Therapeutics, Inc. Announces Affiliation With David G. Armstrong DPM MD PhD the Most Noted Authority on the Diabetic Foot </strong></div><div class="text-block-15">June 06, 2023</div></div></a><a data-w-id="b3167799-6507-7b64-b552-43e3fd9c5c37" style="opacity:0" href="https://cdn.prod.website-files.com/5d929ea754fd0f4955087956/613961449f112e3b46602886_PR%209-6-21%20FINAL%20FINAL%20FINAL.pdf" target="_blank" class="hp-news-trigger-2 w-inline-block"><div class="hp-megaphone-2"></div><div class="div-block-10"><div class="hp-news-title-2"><strong class="bold-text-3">Venturis Therapeutics, Inc. Announces Strategic Alliance with Prevail InfoWorks, Inc. and Prevail Partners, LLC</strong></div><div class="text-block-15">September 09, 2021</div></div></a><a data-w-id="2774598d-fcf3-94db-893d-dafc262f949c" style="opacity:0" href="https://cdn.prod.website-files.com/5d929ea754fd0f4955087956/608c36b4f0b7c7ffa9bb6319_CAD%20patent%20PR%20final%204.29.2021.pdf" target="_blank" class="hp-news-trigger-2 w-inline-block"><div class="hp-megaphone-2"></div><div class="div-block-10"><div class="hp-news-title-2"><strong class="bold-text-3"> Venturis Therapeutics Inc. Announces Granting of US Patent for the Angiogenic Treatment of Ischemic Heart Disease, issued April 6, 2021, with 15 Patent Claims </strong></div><div class="text-block-15">April 30, 2021</div></div></a><a data-w-id="9daf7367-59e9-d36d-49d5-5e58c8d12d61" style="opacity:0" href="https://builtin.com/dallas/biotech-companies-in-dallas" class="hp-news-trigger-2 w-inline-block"><div class="hp-megaphone-2"></div><div class="div-block-10"><div class="hp-news-title-2"><strong class="bold-text-3">15 Dallas Biotech Companies turning the Lone Star State into a Life Sciences leader</strong></div><div class="text-block-15">July 06, 2020</div></div></a><a data-w-id="87dd1bce-6326-42dd-1393-5e9f3bac932f" style="opacity:0" href="https://cdn.prod.website-files.com/5d929ea754fd0f4955087956/5eb46d5847df2f13bad9f36d_Venturis%20Press%20Release%205-5-20%20Final%20V5.pdf" target="_blank" class="hp-news-trigger-2 w-inline-block"><div class="hp-megaphone-2"></div><div class="div-block-10"><div class="hp-news-title-2"><strong class="bold-text-3">Venturis Therapeutics, Inc. Announces its Applications for Four New Patents Related to the Use of Therapeutic Angiogenesis in the Treatment of Illnesses Related to the COVID - 19 Virus, as Well as Illnesses Related to Other Viruses </strong></div><div class="text-block-15"> May 5, 2020 </div></div></a><a data-w-id="1c7c258a-f02a-d550-3cf2-2a718ae46bd9" style="opacity:0" href="https://www.pm360online.com/pm360s-investor-portfolio-mary-schaheen/" target="_blank" class="hp-news-trigger-2 w-inline-block"><div class="hp-megaphone-2"></div><div class="div-block-10"><div class="hp-news-title-2"><strong class="bold-text-3">PM360’s Investor Portfolio: Mary Schaheen</strong></div><div class="text-block-15">September 03, 2019</div></div></a></div><div id="w-node-b666d6df-e960-446e-cccd-282f924ea343-cedf1bf5" class="div-block-28"><div style="padding-top:56.17021276595745%;opacity:0" data-w-id="5ebd673a-05c4-226f-6dfc-910614b94253" class="w-embed-youtubevideo youtube"><iframe src="https://www.youtube.com/embed/HLPwum4AqTM?rel=0&amp;controls=1&amp;autoplay=0&amp;mute=0&amp;start=0" frameBorder="0" style="position:absolute;left:0;top:0;width:100%;height:100%;pointer-events:auto" allow="autoplay; encrypted-media" allowfullscreen="" title=""></iframe></div></div><div id="w-node-e86db79d-f021-ce62-ec75-0e716b6cb945-cedf1bf5" data-w-id="e86db79d-f021-ce62-ec75-0e716b6cb945" style="opacity:0" class="text-block-14">Peter Jennings - ABC World News report on Venturis&#x27; Heart Trial</div></div></div></div><div class="section-6"><div class="container-14 w-container"></div><div data-w-id="02165372-c51e-164a-b1e2-106590715e27" style="-webkit-transform:translate3d(0, 40PX, 0) scale3d(1, 1, 1) rotateX(0) rotateY(0) rotateZ(0) skew(0, 0);-moz-transform:translate3d(0, 40PX, 0) scale3d(1, 1, 1) rotateX(0) rotateY(0) rotateZ(0) skew(0, 0);-ms-transform:translate3d(0, 40PX, 0) scale3d(1, 1, 1) rotateX(0) rotateY(0) rotateZ(0) skew(0, 0);transform:translate3d(0, 40PX, 0) scale3d(1, 1, 1) rotateX(0) rotateY(0) rotateZ(0) skew(0, 0);opacity:0" class="container-12 container-13 w-container"><a href="#Home-Stats" class="link-block-2 w-inline-block"><div class="div-block-27"><img src="https://cdn.prod.website-files.com/5d929ea754fd0f4955087956/5d929ea754fd0f0b3508798a_Arrow02.svg" width="25" style="-webkit-transform:translate3d(0, -15PX, 0) scale3d(1, 1, 1) rotateX(0) rotateY(0) rotateZ(0) skew(0, 0);-moz-transform:translate3d(0, -15PX, 0) scale3d(1, 1, 1) rotateX(0) rotateY(0) rotateZ(0) skew(0, 0);-ms-transform:translate3d(0, -15PX, 0) scale3d(1, 1, 1) rotateX(0) rotateY(0) rotateZ(0) skew(0, 0);transform:translate3d(0, -15PX, 0) scale3d(1, 1, 1) rotateX(0) rotateY(0) rotateZ(0) skew(0, 0);opacity:0" data-w-id="e6e26018-1d11-b103-c01c-daeadde52ecd" alt="" class="image-12"/></div></a></div></div><div id="Home-Stats" class="section-3"><div data-w-id="22222949-055b-9f45-bc68-21c12106c492" class="div-block-5"><img src="https://cdn.prod.website-files.com/5d929ea754fd0f4955087956/5d929ea754fd0f2eae087972_Cracked%20Heart.svg" width="85" style="filter:blur(9px);opacity:0" data-w-id="09d64112-7962-8adf-2bdc-dfc6979122fb" alt="" class="image-10"/></div><div data-w-id="73dee1a0-3526-f756-1e42-6622a4fa5709" class="container-5 w-container"><div data-w-id="fe3cee10-406d-6e7d-20be-041716f4df1c" style="opacity:0;-webkit-transform:translate3d(0, 20PX, 0) scale3d(1, 1, 1) rotateX(0) rotateY(0) rotateZ(0) skew(0, 0);-moz-transform:translate3d(0, 20PX, 0) scale3d(1, 1, 1) rotateX(0) rotateY(0) rotateZ(0) skew(0, 0);-ms-transform:translate3d(0, 20PX, 0) scale3d(1, 1, 1) rotateX(0) rotateY(0) rotateZ(0) skew(0, 0);transform:translate3d(0, 20PX, 0) scale3d(1, 1, 1) rotateX(0) rotateY(0) rotateZ(0) skew(0, 0);filter:blur(5px)" class="text-block-3">An estimated 92,100,000 American adults (more than 1 in 3) have one or more types of cardiovascular disease (CVD). 2,300 Americans die of CVD each day, an average of one death every 38 seconds.</div><div data-w-id="10d1eb47-d19a-cec9-9c16-268af4f54635" style="opacity:0" class="text-block-4">American Heart Association, &quot;Heart Disease and Stroke Statistics-2018 Update&quot;</div></div></div><div class="footer no-top-padding no-bottom-padding"><div id="w-node-_1f206106-a43b-c081-2f79-268b4e2893cc-cedf1bf5" class="container-4 w-container"><div id="w-node-_8f389df1-dfb9-1970-a710-71f3a3f7e6ae-cedf1bf5" class="footer-v4-about"><img src="https://cdn.prod.website-files.com/5d929ea754fd0f4955087956/5d929ea754fd0f3f9a087975_Vascular_tree_Red.jpg" width="63" alt="" class="image-8"/><p class="paragraph-small">Venturis Therapeutics, Inc. is a biopharmaceutical company developing protein drug candidates to address diseases such as diabetic wounds, severe coronary heart disease, and peripheral artery disease.</p></div><div class="footer-v5-about right"><p class="footer-contact-info title">Contact Information</p><p class="footer-contact-info right">2626 Cole Avenue, Suite 300 <br/>Dallas, Texas 75204</p><p class="footer-contact-info right">(972) 904-2029</p></div></div></div><div class="footer-under no-top-padding no-bottom-padding"><div class="w-container"><div class="footer-bottom">© Copyright  2023  Venturis Therapeutics  |  All Rights Reserved</div></div></div><script src="https://d3e54v103j8qbb.cloudfront.net/js/jquery-3.5.1.min.dc5e7f18c8.js?site=5d929ea754fd0f4955087956" type="text/javascript" integrity="sha256-9/aliU8dGd2tb6OSsuzixeV4y/faTqgFtohetphbbj0=" crossorigin="anonymous"></script><script src="https://cdn.prod.website-files.com/5d929ea754fd0f4955087956/js/webflow.9ac5a7b42339ac63fdce978675ae947c.js" type="text/javascript"></script></body></html>

Whois info of domain

Domain Name: CVBT.COM
Registry Domain ID: 27361603_DOMAIN_COM-VRSN
Registrar WHOIS Server: whois.networksolutions.com
Registrar URL: http://networksolutions.com
Updated Date: 2024-03-19T06:15:33Z
Creation Date: 2000-05-18T12:10:38Z
Registry Expiry Date: 2026-05-18T12:10:38Z
Registrar: Network Solutions, LLC
Registrar IANA ID: 2
Registrar Abuse Contact Email: [email protected]
Registrar Abuse Contact Phone: +1.8777228662
Domain Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited
Name Server: NS59.WORLDNIC.COM
Name Server: NS60.WORLDNIC.COM
DNSSEC: unsigned
URL of the ICANN Whois Inaccuracy Complaint Form: https://www.icann.org/wicf/
>>> Last update of whois database: 2025-05-16T16:18:57Z <<<
For more information on Whois status codes, please visit https://icann.org/epp
NOTICE: The expiration date displayed in this record is the date the
TERMS OF USE: You are not authorized to access or query our Whois
by the following terms of use: You agree that you may use this Data only
to: (1) allow, enable, or otherwise support the transmission of mass